Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience

Second-line anti-TNFα therapy with adalimumab is effective at both inducing remission and maintaining response in CD patients who have failed infliximab, regardless of the reason for infliximab failure.